Clinical Trials Sponsored by Pinteon Therapeutics, Inc

Total 3006 results

Tobira Therapeutics, Inc.

Completed

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Healthy

United States
Melinta Therapeutics, Inc.

Completed

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue Infections

United States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
Aciex Therapeutics, Inc.

Completed

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Allergic Conjunctivitis

United States
Millendo Therapeutics, Inc.

Completed

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Adrenocortical Carcinoma | Adrenal Cancer | ACC

United States, Germany
Anika Therapeutics, Inc.

Completed

Safety Study of Cosmetic Tissue Augmentation in People of Color

Wrinkles

United States
Aciex Therapeutics, Inc.

Completed

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Healthy

United States
Aciex Therapeutics, Inc.

Completed

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Atopic Disease (Including Allergic Conjunctivitis)

United States
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Elcelyx Therapeutics, Inc.

Completed

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Type 2 Diabetes Mellitus
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Intrepid Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Androgenetic Alopecia

United States
Melinta Therapeutics, Inc.

Completed

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia

United States, Canada
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Vyne Therapeutics Inc.

Completed

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Rosacea | Papulopustular Rosacea

Germany
BlackThorn Therapeutics, Inc.

Completed

A Study of LY2940094 in Major Depressive Disorder

Major Depressive Disorder

Canada
Nivalis Therapeutics, Inc.

Completed

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) ((SNO-9))

Cystic Fibrosis

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Alcresta Therapeutics, Inc.

Completed

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Exocrine Pancreatic Insufficiency

United States
Nivalis Therapeutics, Inc.

Unknown

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor (SNO-7)

Cystic Fibrosis

United States
Nivalis Therapeutics, Inc.

Completed

PK Study of N91115 in Cystic Fibrosis Patients (SNO3)

Cystic Fibrosis

United States
Mast Therapeutics, Inc.

Completed

Evaluation of Repeat Administration of Purified Poloxamer 188 (EPIC-E)

Sickle Cell Disease

United States
Carbylan Therapeutics, Inc.

Completed

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

Osteoarthritis of the Knee

Canada, Australia, Netherlands Antilles
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Revance Therapeutics, Inc.

Completed

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Lisata Therapeutics, Inc.

Completed

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

ST Segment Elevation Myocardial Infarction

United States
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Opexa Therapeutics, Inc.

Terminated

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (OLTERMS)

Clinically Isolated Syndrome | Multiple Sclerosis, Relapsing-Remitting

United States
INSYS Therapeutics Inc

Completed

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

Healthy

United States
Topokine Therapeutics, Inc.

Completed

Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers

Healthy
Orexigen Therapeutics, Inc

Completed

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Obesity | Overweight

United States
Onconova Therapeutics, Inc.

Terminated

Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia

Lymphoma | Acute Lymphocytic Leukemia

United States
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

Pharmacokinetics and Pharmacodynamics

United States
CymaBay Therapeutics, Inc.

Completed

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

Gout

United States, Canada, Georgia
Mirati Therapeutics Inc.

Terminated

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Completed

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
PNP Therapeutics, Inc.

Completed

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

Head and Neck Cancer

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States

3

Subscribe